康泰生物：重组乙型肝炎疫苗（酿酒酵母）（60μg）获临床试验批准

Core Viewpoint - The company has received approval from the National Medical Products Administration for its recombinant hepatitis B vaccine (yeast) to conduct clinical trials in a new target population [1] Group 1 - The vaccine is specifically approved for use in patients with chronic hepatitis B who have achieved functional (clinical) cure [1] - The approval is in accordance with the Drug Administration Law of the People's Republic of China and the Vaccine Administration Law of the People's Republic of China [1] - The clinical trial aims to prevent the recurrence of HBsAg positivity in the specified population [1]